Rp902

Phase 2

RRisen (Suzhou) Pharma Tech Co., Ltd.

Rp902 is one of 5 therapeutic programs targeting Mild Cognitive Impairment (MCI). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Mild Cognitive Impairment (MCI)Not yet recruiting

Mild Cognitive Impairment (MCI)Phase 2

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Mild Cognitive Impairment (MCI)

#DrugCompanyPhaseTrials

Emtriva

Gilead

Phase 1

1 2

KDS2010

NNeuroBiogen Co., Ltd

Phase 2

1 3

Rp902

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 2

1 4

Gamma- Glutamylcysteine

PPravat Mandal

Phase 1

1 5

TAF/FTC

GGöteborg University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Mild Cognitive Impairment (MCI)

NCT07579884

Clinical

Trials by Indication[1]

Mild Cognitive Impairment (MCI)1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of RP902 Tablets in the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease

Not yet recruiting·RRisen (Suzhou) Pharma Tech Co., Ltd.·Phase 2·NCT07579884·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rp902. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rp902. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Risen (Suzhou) Pharma Tech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRisen (Suzhou) Pharma Tech Co., Ltd.

Rp902

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Mild Cognitive Impairment (MCI)1 trial

References

Drug Info

Quick Facts

Related News